Restricted accessResearch articleFirst published online 2015-03
Prevalence of Anti–Adeno-Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross-Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy Trial
Recombinant vectors based on adeno-associated virus serotype 8 (AAV8) have been successfully used in the clinic and hold great promise for liver-directed gene therapy. Preexisting immunity against AAV8 or the development of antibodies against the therapeutic transgene product might negatively affect the outcomes of gene therapy. In the prospect of an AAV8-mediated, liver-directed gene therapy clinical trial for mucopolysaccharidosis VI (MPS VI), a lysosomal storage disorder caused by arylsulfatase B (ARSB) deficiency, we investigated in a multiethnic cohort of MPS VI patients the prevalence of neutralizing antibodies (Nab) to AAV8 and the presence of ARSB cross-reactive immunologic material (CRIM), which will either affect the efficacy of gene transfer or the duration of phenotypic correction. Thirty-six MPS VI subjects included in the study harbored 45 (62.5%) missense, 13 (18%) nonsense, 9 (12.5%) frameshift (2 insertions and 7 deletions), and 5 (7%) splicing ARSB mutations. The detection of ARSB protein in 24 patients out of 34 (71%) was predicted by the type of mutations. Preexisting Nab to AAV8 were undetectable in 19/33 (58%) analyzed patients. Twelve out of 31 patients (39%) tested were both negative for Nab to AAV8 and CRIM-positive. In conclusion, this study allows estimating the number of MPS VI patients eligible for a gene therapy trial by intravenous injections of AAV8.
Get full access to this article
View all access options for this article.
References
1.
NeufeldE, MuenzerJ. The mucopolysaccharidoses. In: The Online Metabolic and Molecular Bases of Inherited Disease. ScriverR, ed. (McGraw Hill, New York). 2010; pp. 1–73.
2.
GiuglianiR, LampeC, GuffonN, et al.Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet A, 2014; 164A:1953–1964.
3.
WyattK, HenleyW, AndersonL, et al.The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess, 2012; 16:1–543.
4.
HarmatzP, GiuglianiR, SchwartzI, et al.Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr, 2006; 148:533–539.
5.
CotugnoG, AnnunziataP, BaroneMV, et al.Impact of age at administration, lysosomal storage, and transgene regulatory elements on AAV2/8-mediated rat liver transduction. PLoS One, 2012; 7:e33286.
6.
GaoGP, AlviraMR, WangL, et al.Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA, 2002; 99:11854–11859.
7.
NathwaniAC, RosalesC, McIntoshJ, et al.Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther, 2011; 19:876–885.
8.
WangL, WangH, BellP, et al.Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol Ther, 2010; 18:118–125.
9.
CotugnoG, TessitoreA, CapalboA, et al.Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Hum Gene Ther, 2010; 21:555–569.
10.
CotugnoG, AnnunziataP, TessitoreA, et al.Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol Ther, 2011; 19:461–469.
11.
FerlaR, O'MalleyT, CalcedoR, et al.Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8. Hum Gene Ther, 2013; 24:163–169.
12.
FerlaR, ClaudianiP, CotugnoG, et al.Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease. Hum Gene Ther, 2014; 25:609–618.
13.
TessitoreA, FaellaA, O'MalleyT, et al.Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. Mol Ther, 2008; 16:30–37.
14.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
15.
NathwaniAC, TuddenhamEG, RangarajanS, et al.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011; 365:2357–2365.
16.
WangL, CalcedoR, WangH, et al.The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther, 2010; 18:126–134.
17.
WangL, CalcedoR, BellP, et al.Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther, 2011; 22:1389–1401.
18.
LoDucaPA, HoffmanBE, HerzogRW. Hepatic gene transfer as a means of tolerance induction to transgene products. Curr Gene Ther, 2009; 9:104–114.
19.
AnnoniA, CantoreA, Della ValleP, et al.Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. EMBO Mol Med, 2013; 5:1684–1697.
20.
MarkusicDM, HoffmanBE, PerrinGQ, et al.Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med, 2013; 5:1698–1709.
21.
MeiklePJ, GrasbyDJ, DeanCJ, et al.Newborn screening for lysosomal storage disorders. Mol Genet Metab, 2006; 88:307–314.
22.
CalcedoR, VandenbergheLH, GaoG, et al.Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis, 2009; 199:381–390.
23.
BrandsMM, Hoogeveen-WesterveldM, KroosMA, et al.Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase. Orphanet J Rare Dis, 2013; 8:51.
24.
Di NataleP, VillaniGR, PariniR, et al.Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease. Biotechnol Appl Biochem, 2008; 49:219–223.
25.
VillaniGR, GrossoM, PontarelliG, et al.Large deletion involving exon 5 of the arylsulfatase B gene caused apparent homozygosity in a mucopolysaccharidosis type VI patient. Genet Test Mol Biomarkers, 2010; 14:113–120.
26.
LitjensT, BrooksDA, PetersC, et al.Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet, 1996; 58:1127–1134.
27.
MingozziF, HighKA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet, 2011; 12:341–355.
28.
DavidoffAM. AAV-8 Mediated Gene Therapy for Hemophilia B—Oral Communication. American Society of Cell and Gene Therapy, Washington, DC, 2014.
29.
MingozziF, HighKA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 2013; 122:23–36.
30.
MingozziF, AnguelaXM, PavaniG, et al.Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 2013; 5:194ra92.
31.
BoutinS, MonteilhetV, VeronP, et al.Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther, 2010; 21:704–712.
32.
MimuroJ, MizukamiH, ShimaM, et al.The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. J Med Virol, 2014; 86:1990–1997.
33.
CalcedoR, WilsonJM. Humoral immune response to AAV. Front Immunol, 2013; 4:341.
34.
CalcedoR, MorizonoH, WangL, et al.Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol, 2011; 18:1586–1588.
35.
HarmatzP, GiuglianiR, SchwartzIV, et al.Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab, 2008; 94:469–475.
36.
D'AvolaD, Lopez-FrancoE, HarperP, et al.Phase I clinical trial of liver directed gene therapy with rAAV5/2-PBGD in acute intermittent porphyria: safety data. European Society of Cell and Gene Therapy Abstract OR036, 2014.
37.
KarageorgosL, BrooksDA, PollardA, et al.Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat, 2007; 28:897–903.
38.
HarmatzP, WhitleyCB, WaberL, et al.Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr, 2004; 144:574–580.
39.
HarmatzP, KetteridgeD, GiuglianiR, et al.Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics, 2005; 115:e681–e689.
40.
HarmatzP, KramerWG, HopwoodJJ, et al.Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatr, 2005; 94:61–68; discussion 57.
41.
IsbrandtD, ArltG, BrooksDA, HopwoodJJ, et al.Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes. Am J Hum Genet, 1994; 54:454–463.
42.
LinWD, LinSP, WangCH, HwuWL, et al.Genetic analysis of mucopolysaccharidosis type VI in Taiwanese patients. Clin Chim Acta, 2008; 394:89–93.
43.
KarageorgosL, HarmatzP, SimonJ, PollardA, et al.Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy. Hum Mutat, 2004; 23:229–233.
44.
VoskoboevaE, Krasnopol'skaiaKD, PetersK, von FiguraK. [Identification of mutations in the arylsulfatase B gene in Russian mucopolysaccharidosis type VI patients]. Genetika, 2000; 36:837–843.
45.
ArltG, BrooksDA, IsbrandtD, HopwoodJJ, et al.Juvenile form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). A C-terminal extension causes instability but increases catalytic efficiency of arylsulfatase B. J Biol Chem, 1994; 269:9638–9643.
46.
VoskoboevaE, IsbrandtD, von FiguraK, KrasnopolskayaX, et al.Four novel mutant alleles of the arylsulfatase B gene in two patients with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Hum Genet, 1994; 93:259–264.
47.
BrooksDA, GibsonGJ, KarageorgosL, HeinLK, et al.An index case for the attenuated end of the mucopolysaccharidosis type VI clinical spectrum. Mol Genet Metab, 2005; 85:236–238.
48.
KantaputraPN, KayseriliH, GuvenY, KantaputraW, et al.Clinical manifestations of 17 patients affected with mucopolysaccharidosis type VI and eight novel ARSB mutations. Am J Med Genet A, 2014; 164A:1443–1453.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
